Pancreatic cancer: The RAS paradigm shift
Treatment approaches for pancreatic adenocarcinoma, an aggressive disease with poor prognosis, are evolving beyond cytotoxic chemotherapy. Recent advances in RAS targeting with small molecules are redefining therapeutic paradigms.
Authors
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Samuel P. Soff (ORCID: https://orcid.org/0000-0001-5851-6075)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Weill Cornell Medicine (US)
Publication Details
- Journal
- PLoS Medicine
- Published
- 2026-10-29
- DOI
- https://doi.org/10.1371/journal.pmed.1005283
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Society of Clinical Oncology
- Break Through Cancer
- National Institutes of Health
- National Cancer Institute